Tehran University of Medical Sciences Iranian Journal of Allergy, Asthma and Immunology 1735-1502 0 0 2026 06 16 1 6 Shuai Fu Department of Pharmacy, The People’s Hospital of Danyang, Danyang, Jiangsu, China Jiguang Lu Department of Pharmacy, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu, China Qinwen Zhu Department of Pharmacy, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu, China Bin Yang Department of ENT, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu, China Zhiwei Liu Department of Pharmacy, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, China Xinyan Liu Department of Pharmacy, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu, China Jinglin Tian Department of Pharmacy, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, Jiangsu, China 2025 12 17 2026 01 30 This meta-analysis was conducted to investigate the efficacy and safety of omalizumab in the treatment of allergic rhinitis in adults. Randomized controlled trials (RCTs) on omalizumab in the treatment of allergic rhinitis in adults were collected by searching PubMed, Cochrane Library, Embase, Web of Science, CNKI, VIP, and Wanfang Data. The search period was from the establishment of each database to October 2024. Stata 15.0 software was used for data analysis. The control group received a placebo or other anti-allergy drugs, while the experimental group received omalizumab, with or without specific immunotherapy. A total of 8 RCTs were involved in this meta-analysis. The combined analysis exhibited that the effective rate was higher in the omalizumab group than in the control group (RR=1.15; 95% CI, 1.06–1.24) for allergic rhinitis. IgE levels (SMD=−2.82; 95% CI, −4.03 to −1.62) and DNSS (SMD=−1.99; 95% CI, −3.04 to −0.94), DOSS (SMD=−2.95; 95% CI, −4.65 to −1.25) were lower in the omalizumab group compared with the control group. No significant difference was observed in the incidence of adverse events between the two groups (RR=1.15; 95% CI, 0.69–1.93). Omalizumab is effective and safe in the treatment of adult allergic rhinitis. https://ijaai.tums.ac.ir/index.php/ijaai/article/view/4703 https://ijaai.tums.ac.ir/index.php/ijaai/article/download/4703/2357